IP Library › Granted Patent US 11,472,850
Granted Patent B2
US 11,472,850 · App. 17/060,067 · Granted Oct 18, 2022

Patent

Inventors: Annaliesa Sybil Anderson (Upper Saddle River, NJ); Susan Kay Hoiseth (Tampa, FL); Kathrin Ute Jansen (New York, NY); Justin Keith Moran (West Nyack, NY); Mark Edward Ruppen (Cresco, PA)
Assignee: Pfizer Inc.
C07K14/22A61K39/095A61K2039/55505A61K2039/58A61K2039/6037A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,472,850
App. No.
17/060,067
Granted
Oct 18, 2022
Kind
B2
Abstract

In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

Claims (29)

1. A method of eliciting an immune response against Neisseria meningitidis comprising administering to a mammal an effective amount of:

A) a first composition comprising:

(i) a first polypeptide comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NO: 55; (6) SEQ ID NO: 76; (c) SEQ ID NO: 77; and (d) SEQ ID NO: 13;

(ii) a second polypeptide comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NO: 21 and (b) SEQ ID NO: 44;

wherein the first composition comprises aluminum; and

B) a second composition comprising:

(a) a Neisseria meningitidis serogroup A (MenA) capsular saccharide conjugated to CRM 197 ;

(b) a Neisseria meningitidis serogroup C (MenC) capsular saccharide conjugated to CRM 197 ;

(c) a Neisseria meningitidis serogroup W135 (MenW) capsular saccharide conjugated to CRM 197 ; and

(d) a Neisseria meningitidis serogroup Y (MenY) capsular saccharide conjugated to CRM 197 .

2. The method according to claim 1 , wherein the first polypeptide comprises the amino acid sequence SEQ ID NO: 55.

3. The method according to claim 1 , wherein the first polypeptide comprises the amino acid sequence SEQ ID NO: 76.

4. The method according to claim 1 , wherein the first polypeptide comprises the amino acid sequence SEQ ID NO: 77.

5. The method according to claim 1 , wherein the second polypeptide comprises the amino acid sequence SEQ ID NO: 44.

6. The method according to claim 1 , wherein the first composition further comprises a third polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 18; SEQ ID NO: 49; and SEQ ID NO: 50.

7. The method according to claim 1 , wherein the first composition further comprises a third polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 19; SEQ ID NO: 61; and SEQ ID NO: 75.

8. The method according to claim 1 , wherein the first composition further comprises a third polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 18; SEQ ID NO: 49; and SEQ ID NO: 50; and a fourth polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 19; SEQ ID NO: 61; and SEQ ID NO: 75.

9. The method according to claim 1 , wherein the immune response is against a Neisseria meningitidis serogroup B strain.

10. The method according to claim 1 , wherein the immune response is against a Neisseria meningitidis serogroup C strain.

11. The method according to claim 10 , wherein the strain expresses factor H binding protein A68.

12. The method according to claim 10 , wherein the strain expresses factor H binding protein B24.

13. The method according to claim 1 , wherein the immune response is against a Neisseria meningitidis serogroup Y strain.

14. The method according to claim 13 , wherein the strain expresses factor H binding protein A121.

15. The method according to claim 13 , wherein the strain expresses factor H binding protein B09.

16. The method according to claim 1 , wherein the second composition comprises 10 μg MenA oligosaccharides, 5 μg of MenC oligosaccharides, 5 μg of MenY oligosaccharides, and 5 μg of MenW-135 oligosaccharides.

17. The method according to claim 1 , wherein the second composition further comprises residual formaldehyde.

18. The method according to claim 1 , wherein the first composition further comprises polysorbate-80.

19. The method according to claim 1 , wherein the first composition further comprises trehalose.

20. The method according to claim 1 , wherein the first composition and the second composition are administered concomitantly.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →